Patents by Inventor Paul E. Fleming

Paul E. Fleming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20140107160
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: October 9, 2013
    Publication date: April 17, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C.B. Harriman, Zhan Shi, B. Shaowu Chen
  • PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME
    Publication number: 20140088096
    Abstract: Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, XY, RY1, RY2 and RY3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.
    Type: Application
    Filed: February 14, 2013
    Publication date: March 27, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Roushan Afroze, Indu T. Bharathan, Jeffrey P. Ciavarri, Paul E. Fleming, Jeffrey L. Gaulin, Mario Girard, Steven P. Langston, Francois Soucy, Tzu-Tshin Wong, Yingchun Ye
  • Derivatives of 1-amino-2-cyclobutylethylboronic acid
    Patent number: 8664200
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: March 4, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID
    Publication number: 20140011998
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 9, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • CCR9 inhibitors and methods of use thereof
    Patent number: 8569543
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: October 29, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • Derivatives of 1-amino-2-cyclopropylethylboronic acid
    Patent number: 8513218
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: August 20, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
    Patent number: 8268822
    Abstract: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: September 18, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Zhan Shi, Brendan Shaowu Chen, Jane F. Schmidt, John C. Reader, Neal D. Hone, Jeffrey P. Ciavarri
  • DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID
    Publication number: 20110245203
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: October 6, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • CCR9 inhibitors and methods of use thereof
    Patent number: 8030517
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: October 4, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • CCR9 inhibitors and methods of use thereof
    Patent number: 7999109
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: August 16, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • Beta-carbolines useful for treating inflammatory disease
    Patent number: 7951801
    Abstract: This invention provides beta-carboline compounds of formula III-A-aa: wherein Q, G, R1, R2, R3, and R6b are as described in the specification. The compounds are useful for treating diseases such as inflammatory diseases and cancer.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: May 31, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael E. Hepperle, Julie Fields Liu, Francois Soucy, Prakash Raman, Jeremy D. Little, Paul E. Fleming, Dominic Reynolds, Geraldine C. B. Harriman
  • 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20110071134
    Abstract: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:
    Type: Application
    Filed: April 26, 2010
    Publication date: March 24, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Zhan Shi, Brendan S. Chen, Jane F. Schmidt, John C. Reader, Neal D. Hone, Jeffrey P. Ciavarri
  • 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
    Patent number: 7732444
    Abstract: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: June 8, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Zhan Shi, Brendan S. Chen, Jane F. Schmidt, John C. Reader, Neal D. Hone, Jeffrey P. Ciavarri
  • Beta-carbolines useful for treating inflammatory disease
    Patent number: 7727985
    Abstract: This invention provides beta-carboline compounds of formula I: wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2-mediated diseases such as inflammatory diseases and cancer.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: June 1, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael E. Hepperle, Julie Fields Liu, Francois Soucy, Yingchun Ye, Robert S. Murray, Raman Prakash, Jeremy D. Little, Alfredo Castro, Hormoz Mazdiyasni, Paul E. Fleming, Dominic Reynolds
  • BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE
    Publication number: 20100093713
    Abstract: This invention provides beta-carboline compounds of formula wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2-mediated diseases such as inflammatory diseases and cancer.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 15, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Michael E. Hepperle, Julie Fields Liu, Francois Soucy, Yingchun Ye, Robert S. Murray, Raman Prakash, Jeremy D. Little, Alfredo Castro, Hormoz Mazdiyasni, Paul E. Fleming, Dominic Reynolds
  • Derivatives of 1-amino-2-cyclobutylethylboronic acid
    Publication number: 20100081633
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 1, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Beta-carbolines useful for treating inflammatory disease
    Publication number: 20040235839
    Abstract: This invention provides beta-carboline compounds of formula I: 1
    Type: Application
    Filed: April 9, 2004
    Publication date: November 25, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Michael E. Hepperle, Julie Fields Liu, Francois Soucy, Yingchun Ye, Robert S. Murray, Raman Prakash, Jeremy D. Little, Alfredo Castro, Hormoz Mazdiyasni, Paul E. Fleming, Dominic Reynolds